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DDX4 (the human ortholog of Drosophila Vasa) is an RNA helicase and is present
in the germ lines of all metazoans tested. It was historically thought to be
expressed specifically in germline, but with additional organisms studied, it is
now clear that in some animals DDX4/Vasa functions outside of the germline, in
a variety of somatic cells in the embryo and in the adult. In this report, we docu-
ment that DDX4 is widely expressed in soma-derived cancer cell lines, including
myeloma (IM-9) and leukemia (THP-1) cells. In these cells, the DDX4 protein local-
ized to the mitotic spindle, consistent with findings in other somatic cell func-
tions, and its knockout in IM-9 cells compromised cell proliferation and migration
activities, and downregulated several cell cycle/oncogene factors such as CyclinB
and the transcription factor E2F1. These results suggest that DDX4 positively reg-
ulates cell cycle progression of diverse somatic-derived blood cancer cells, imply-
ing its broad contributions to the cancer cell phenotype and serves as a potential
new target for chemotherapy.
T he germ line and cancer cells share various cellular char-acteristics important for their functions. Notable shared
traits include: (i) periods of hyperproliferation relative to their
neighbors, such as in the gonial stem cells within the presump-
tive gonad, and in tumor growth;(1) and (ii) extensive migra-
tion of the primordial germ cells from their site of formation
to the gonadal ridge, and metastasis in cancer cells, which
accounts for approximately 90% of human cancer deaths.(2) It
has long been proposed that similar mechanisms of regulation
may be found in these otherwise disparate cell types.(3)
Several germline factors widely conserved throughout meta-
zoans appear to be associated with tumors. For instance, Nanos
(RNA-binding protein) upregulation as a consequence of Rb
(Retinoblastoma) inactivation causes inhibition of apoptotic
genes and promotes cell proliferation.(4) PIWI (a small RNA
regulator) has been reported to be linked to many hallmarks of
cancer, including cell proliferation, anti-apoptosis, genomic
instability, and metastasis.(5,6) These emerging functions of
germline factors led us to suggest that germline factors may
contribute broadly to cancer cell regulation.
DDX4, a Drosophila Vasa ortholog, is another conserved
germline factor in metazoans.(7,8) It is a DEAD box RNA heli-
case and is implicated in translational regulation of germline-
specific molecules in various organisms.(9–13) In mammals,
DDX4 is expressed in germ cells of both sexes and functions
in germline formation and maintenance. Recent reports in sev-
eral organisms, however, suggest that Vasa also functions in
embryonic and adult somatic cells, in regenerative tissues, and,
in some cases, in tumorigenic cells.(14–19) Particularly, the find-
ing of broad germline factor expression in a malignant brain
tumor in the fly Drosophila melanogaster strongly supported
the contention of not just germline factor presence, but of
germline factor function in tumorigenic cells.(18) In the Janic
et al.(18) study, Drosophila brain tumors regressed when one
or another of the germline factors was inactivated, indicating
that these germline factors were essential for certain character-
istics of tumor formation and/or maintenance, at least in this
type of malignancy. Furthermore, it has been reported that
DDX4 is expressed in several ovarian cancer cells and tissues,
and its overexpression accelerates cell cycle progression by
abrogating the G2 checkpoint.
(20,21) These observations, both in
normal somatic cells and in cancerous cells, suggest that when
DDX4/Vasa is expressed, it appears to be consistently involved
in cellular proliferation, potentially through its function as a
translational regulator. However, its direct contribution and
detailed functional mechanisms in normal somatic cells, or in
somatic cell cancers, are unclear. In this study, we report that
DDX4 is consistently localized with the mitotic apparatus in
various blood-derived cancer cell lines and has essential roles
in cell proliferation and migration – the functionalities for
which DDX4/Vasa is also involved in the germ line.
Materials and Methods
Cell lines, cell culture, and cell number counting. Multiple
myeloma cell lines IM-9 (ATCC# CCL-159, Manassas, VA,
USA), MM.1S (ATCC# CRL-2974, Manassas, VA, USA),
KMS11 (NCIt # C3242, Baltimore, MD, USA), and OPM-2
(DSMZ # ACC 50, Leibniz Institute, Braunschweig, Germany)
and acute monocytic leukemia cell line THP-1 (ATCC# TIB-
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202, Manassas, VA, USA) were cultured in RPMI-1640 sup-
plemented with 10% (v/v) heat-inactivated FBS (Thermo
Fisher Scientific, Waltham, MA, USA) and antibiotics in a
humidified atmosphere of 95% air and 5% CO2 at 37°C. RNAs
of human embryonic cells were obtained as a gift from Dr.
Ryoichi Sugimura (Harvard University, Boston, MA, USA).
For all experiments, cells in the log phase of growth were
used. For counting cell numbers, each cell line was suspended
at 1 9 105/mL and counted on a hemocytometer every 3 days
of culture five times, independently.
Clustered regularly interspaced short palindromic repeats
(CRISPR)-mediated DDX4 gene manipulation in IM-9 cells . Len-
tiviral vectors for CRISPR-mediated DDX4 knockout was con-
structed using the LentiCRISPRv2 vector (Addgene #52961,
Cambridge, MA, USA) following the protocol described in
Shalem et al.(22) and Sanjana et al.(23) This vector coexpresses
a mammalian codon-optimized Cas9 nuclease along with a sin-
gle guide RNA to facilitate genome editing. Three guide RNAs
(gRNAs) were designed within the third exon of the DDX4
gene locus (Table S1). A scrambled gRNA sequence formed
by a random combination of A, G, T, and C, which does not
share identity with either the mouse or human genome, was
used as a control. Lentiviral infection was carried out as
described in Shalem et al.,(22) followed by a puromycin selec-
tion.
Genomic extraction and genomic PCR. One microliter of each
cell pellet was subjected to genomic DNA extraction by treating
with a final volume of 100 lg/mL proteinase K at 50°C for 3 h,
followed by heat inactivation at 96°C for 15 min. One micro-
liter of each of these proteinase K-treated samples was used for
genomic PCR to amplify a flanking region of the third exon of
DDX4, where the gRNA sequences were designed, using high
fidelity Platinum Taq DNA polymerase (Thermo Fisher Scien-
tific) with primers summarized in Table S1. The resultant PCR
products were either separated by agarose gel electrophoresis
and visualized, or subjected to subcloning into the pGEM Easy
Vector (Promega, Madison, WI, USA) for sequencing.
Reverse transcription–PCR and quantitative real-time PCR.
RNA extraction was carried out using the RNeasy Mini Kit
(Qiagen, Hilden, Germany), and 1 lg each of the resultant
total RNAs were subjected to RT using the Maxima First
Strand cDNA Synthesis Kit (Thermo Fischer Scientific) fol-
lowing the manufacturer’s protocol. The cDNAs (1 lL each)
were then used either for conventional PCR reactions or for
quantitative PCR reactions. Conventional PCR reactions were
carried out with 35 cycles using high fidelity Platinum Taq
DNA polymerase (Thermo Fisher Scientific) with primers sum-
marized in Table S1. Quantitative PCR of the IM-9 cell line
cDNA was undertaken using SYBR Green Master Mix
(Thermo Fisher Scientific). Into each well was placed 1 lL
cDNA, 12.5 lL SYBR Green Master Mix, 6 lL of 10 lM for-
ward and reverse primer mix, and 5.5 lL water. The primers
are summarized in Table S1.
Invasion assay. Invasion assays were carried out using a
Corning Transwell (Corning #3422, Tewksbury, MA, USA)
following the manufacturer’s protocol. Briefly, each cell line
was starved in culture media lacking FBS for a day, and then
each of 1 9 106 cells was placed into the Transwell insert
with FBS attractant at the bottom of the well. After 24 h, the
number of cells that passed through the membrane were
counted. For a negative control, the ORI cell line was placed
into the Transwell insert without the FBS attractant.
Cell staining. 5-Ethynyl-20-deoxyuridine (EdU) (Life Tech-
nologies, Carlsbad, CA, USA) is incorporated during DNA
replication of the cell and thus works as a DNA replication
marker. IM-9 cells were treated with a final 1 mg/mL EdU for
2 h to label replicative cells. L-homopropargylglycine (HPG)
is a glycine derivative and is incorporated as a methionine ana-
log during new protein synthesis and thus works as a vital
method for visualizing nascent protein populations synthesized
at specific times as determined by the reagent exposure. HPG
(50 mM stock solution; Life Technologies) was added to cells
at a 1:1000 dilution (50 lM final concentration) for 3 h in
methionine-depleted DMEM culture media (#21013024;
Thermo Fisher Scientific).
For both the EdU and HPG experiments, as a negative con-
trol, a set of cells with no treatment was also prepared and
subjected to identical detection protocols. The cells were then
fixed with 4% paraformaldehyde in PBS solution and Click-iT
detection was undertaken by following the manufacturer’s pro-
tocol (Life Technologies). After detection the DNA was
stained using HCS NuclearMask Blue Stain (Thermo Fisher
Scientific) at 1:2000 for 30 min. Coverslips were then washed
with PBS and mounted on the slide glass. Five images of each
stained specimen were taken under the fluorescent microscope
(Axioplan; Zeiss, Jena, Germany), and the average number of
positive cells in each image was calculated by Image J (NIH,
https://imagej.nih.gov/ij/). These experiments were also
repeated at least three independent times.
Immunofluorescence. Cells were fixed with 4%
paraformaldehyde at 4°C overnight or 30 min at room temper-
ature, washed with PBS three times, and stained with a pri-
mary antibody against DDX4 (#13840, 43; Abcam,
Cambridge, MA, USA) diluted at 1:300 at room temperature
for 3–5 h. They were washed six times with PBS and stained
with a secondary antibody against rabbit IgG (1:500; 1 mg/
mL, Thermo Fisher Scientific) in PBS. They were then washed
six times and a Hoechst nuclear stain (10 mg/mL; Promega,
Madison, WI, USA) in PBS was applied at a 1:1500 dilution.
The resultant cells were visualized by wide-field fluorescence
microscopy (Axioplan; Zeiss) or by confocal laser microscopy
(LSM510 and LSM800; Zeiss, Jena, Germany).
Immunoblot analysis. Immunoblots were carried out by col-
lecting approximately 10 lL packed cells from each group,
and the resultant samples were prepared in 50 lL loading buf-
fer for PAGE. Each sample (10 lL) was run on a 4–20% gra-
dient Tris–glycine polyacrylamide gel and transferred to
nitrocellulose membranes for immunoblotting with a-tubulin
antibody, DDX4 antibody (#D10C5; Cell Signaling Technol-
ogy, Danvers, MA, USA), MIWI antibody (#2079; Cell Signal-
ing Technology, Dallas, TX, USA), 14-3-3r antibody (#sc-
166473; Santa Cruz Biotechnology) at 1:1000, or with peroxi-
dase-conjugated anti-mouse or anti-rabbit secondary antibodies
at 1:5000 (Life Technologies). The bound antibodies were
detected by incubation in a chemiluminescence solution
(1.25 mM luminol, 68 lM coumeric acid, 0.0093% hydrogen
peroxide, and 0.1 M Tris pH 8.6) for 1–10 min, exposed to
film, and developed. Each experiment was carried out at least
three times, independently.
Results
DDX4 is expressed and localized with the spindle of human
blood cancer cells. Through database searches at the Cancer Cell
Line Encyclopedia(24) and Cancer Genomics Program (http://
www.cancergenomicsprogram.ca/about-cgp), we identified sev-
eral dozen cancer cell lines that are potentially overexpressing
ddx4 transcripts. Among them, 26 of 50 cancer cell lines are
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derived from blood/lymph cells. Therefore, in this study, we
tested for a potential function of this essential germ line factor
on the blood cell-derived cancer cell lines IM-9 and THP-1.
IM-9 (CCL-159; ATCC) is a multiple myeloma-derived B lym-
phocyte and THP-1 (TIB-202; ATCC) is an acute monocytic
leukemia-derived monocyte. To test for DDX4 expression, we
first screened for transcripts using RT-PCR for each cell line.
Expression of another germline factor PIWI-like2 (PIWIL2) that
is known to function with DDX4/Vasa in the germline(25) as
well as in some cancer cells(6,26) was analyzed in parallel. We
learned that both ddx4 and piwil2 mRNA were expressed in
IM-9 and THP-1 cells (Fig. 1a). With the same experimental
conditions, their expression levels were compared with several
other myeloma-derived cell lines as well as in human embryonic
stem cells. Intriguingly, human embryonic stem cells showed
the most robust expression and other myeloma cells such as
KMS-11 and MM1S also showed accumulation of DDX4, yet
no expression was detectable in OPM-2 in this condition. As
negative controls, the same amount of total RNA was used for
reverse transcription without the reverse transcriptase enzyme
(–RT; Fig. 1a), and the resultant “cDNA” showed no amplifica-
tion of any of the target genes, including the housekeeping genes
GAPDH and 36B4 used here as positive controls. These results
suggest that ddx4 and piwil2 mRNAs are indeed transcribed in
several blood-derived cancer cells as well as embryonic stem
cells.
As not all mRNAs are translated into protein to function in
the cell, especially in cases of many germline factors,(27) we
next tested by immunofluorescence whether the DDX4 protein
is present in these cells. In THP-1 and IM-9 cells, DDX4 was
detectable and is localized throughout the cytoplasm. During
M phase in these cells, DDX4 was enriched on the mitotic
apparatus with a granule-like structure. In MM1S, the DDX4
signal was weak yet still enriched the most on the mitotic
apparatus (Fig. 1b, arrows). Cells processed identically, but
without anti-DDX4 antibody, showed no DDX4 signal any-
where in the cell, suggesting the specificity of the DDX4 sig-
nal on the mitotic apparatus. The DDX4 protein expression in
DDX4 + cells was also tested by immunoblotting (Fig. 2).
From these results of protein analysis, we concluded that
DDX4 associates with the spindle during M phase and might
also function in cell cycle regulation in these cancer cells.
Gene targeting to reduce DDX4 protein expression. To test the
possible function of DDX4 in these blood-derived cancer cells,
we constructed DDX4-knockout cell lines in IM-9 cells using
the CRISPR-mediated genome-editing technology.(22,23) IM-9
was chosen here because it has robust DDX4 expression and
proliferates every 12–24 h, allowing a better selection of
knockout cell lines. Three independent gRNAs (C1, C2, and
C3) were designed within the third exon of the DDX4 genomic
locus, and one control gRNA with a scrambled sequence was
designed (SC) without specific targets in the human genome.
The lentivirus vector that contains each of these gRNAs and the
Cas9-expression cassette was introduced into IM-9 cells to con-
struct the knockout cell lines of C1, C2, and C3 as well as the
control cell line of SC (Fig. 2a). The CRISPR-mediated gene
silencing generally occurs through a cut and random repair of
the broken DNA double-strands, called non-homologous end-
joining, within the targeted gene sequence. We analyzed the
outcomes of the genome editing in each cell line by genomic
PCR and sequencing. First, to test for successful lentiviral
infection, the lentiviral vector sequence was detected by PCR.
All of the CRISPR-treated cells (C1, C2, C3, and SC) showed a
distinct band at the expected size for the lentivirus vector
fragment, whereas the original cell lines not treated with
CRISPR (ORI) showed no amplification of any kind with the
same primer sets (Fig. 2b, ii), suggesting a successful infection
and a specific detection. To amplify the CRISPR-targeted
sequence (Fig. 2b, i), primers were designed to amplify the
entire third exon of DDX4 as well as its flanking introns. The
DDX4 genomic sequence was amplified in all cell lines and the
resultant PCR products were subcloned into the pGEM-T easy
vector for individual sequencing of the PCR products. We
found mutations in the third exon of the DDX4 genomic locus
in 100% (n = 7) of the C1 cell lines, 55.6% (n = 9) of C2 cell
lines, and 33.3% (n = 9) in C3 cell lines, whereas no mutation
was found in control SC cell lines (n = 7) or ORI cell lines
(n = 7) (Fig. 2c). We also found a large deletion of the DDX4
genomic locus in the C1 cell line, which may explain the
decreased amplification of the genomic PCR products in this
cell line.
To test whether these genomic mutations successfully inhib-
ited DDX4 protein expression, immunoblot and immunofluo-
rescence were undertaken. The DDX4 protein level and
localization on the mitotic apparatus were decreased signifi-
cantly in C1 and C2, and to some extent in C3 compared to
the control cell line SC (Fig. 2d,e). To be noted, CRISPR-
mediated knockout depends on non-homologous end-joining,
the internal cellular mechanism to repair the broken DNA
strands caused by CRISPR/Cas9. This repair occurs in a ran-
dom manner. It is thus expected to result in different patterns
of deletions within the same cell population as each cell
received CRISPR/Cas9. Because of this randomness within the
population of cells, some of the deletions may cause a frame
shift and completely inhibit protein expression, whereas others
may result in truncated proteins or mutated proteins, but with-
out a frame shift. Cells with such mutations may still express
DDX4 proteins that are functional in some cases. We, there-
fore, were unable to acquire a complete knockout of DDX4
protein in the population immunoblot. This suggests a small
population of cells may still express functional DDX4 proteins,
and the DDX4 signal in C3 is likely incomplete inactivation of
DDX4 protein expression in all cells of the population. A sin-
gle cell culture that requires longer passaging of cells may also
change cellular phenotypes, so we used a stock of cells that
were stored immediately after the lentiviral infection and puro-
mycin selection in this study. Independent knockout cell lines
C1–C3, however, consistently showed decreased DDX4
expression, whereas the control cell line SC showed no reduc-
tion. These results suggest that a significant portion of DDX4
protein expression in the cell was successfully knocked out
through the CRISPR genome-editing approach in these cell
lines. On observation of the cells, we found that the DDX4
knockout cells typically formed incomplete spindles (Fig. 2e)
and no longer proliferated significantly, which is also a consis-
tent phenotype reported in germline stem cells and in some
embryonic cells.(14–16) In this study, however, we emphasize a
population-based study.
DDX4 knockout cells have decreased cell proliferation and
migration. Using the above cell lines, C1, C2, and C3, we ana-
lyzed the effects of DDX4-knockout in cellular activities. Cell
counting revealed that the rate of cell proliferation in the popu-
lation was decreased to 30% in C1 and C2 compared to the
controls, SC and ORI (Fig. 3a). This result suggests that
DDX4 is important for cell proliferation. We also tested
whether DDX4 is important for DNA replication. For this
experiment, each cell line was treated for 2 h with EdU
(nucleotide derivative) that is incorporated into DNA during
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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chromosome replication, serving as a good DNA replication
marker. The proportion of the EdU-positive cells against the
total number of cells was then counted under the fluorescent
microscope (Fig. 3b). The C1 and C2 cells showed decreased
activities in DNA replication, yet the differences compared to
control cells were relatively small. This result suggests that
DDX4 may be necessary for cell proliferation but less so for
S-phase entry and DNA replication.
As DDX4/Vasa is also known to be involved in germ cell
migration in various animals, we next tested whether DDX4
knockout affects activities of cancer cell migration by invasion
assays. In C1 and C2, the number of cells migrated toward the
FBS-containing well were significantly decreased, close to that
of the negative control group (ORI with no FBS-containing
well), whereas C3 showed relatively higher migration activities
but still lower than the positive controls (Fig. 3c). These
results suggest that DDX4 might be important for IM-9 cancer
cell migration. Together, these results suggest that DDX4
activities function in proliferation and migration in IM-9 can-
cer cells.
Fig. 1. Germline factor DDX4 is expressed in
several blood-derived cancer cells. (a) RT-PCR results
of six cell lines (KMS11, THP-1, hES, OPM-2, MM1S,
and IM-9) for four gene products (PIWIL2, DDX4,
GAPDH, and 36B4). Left panels, negative controls
(lacking RT enzyme). Right panels, positive tests. (b)
(i) Immunofluorescence results showing DDX4
localization in five cell types counterstained with
tubulin and DNA. As indicated by arrows, DDX4 is
localized on the mitotic spindle in cancer cells
expressing DDX4. Scale bar = 5 lm. (ii) Relative
signal intensity of DDX4 on the spindle of each cell
line. The signal level of DDX4 was calculated by
Image J and normalized to that of tubulin. The
average relative value of each of the five cells
undergoing mitosis is presented for each cell line.
The value of IM-9 is set at 1.
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DDX4 knockout downregulates expression of cell cycle regula-
tors and oncogenes. As Vasa/DDX4 is an RNA-helicase and
known to function as a translational regulator, the cellular phe-
notypes described above may be due to changes in expression
of DDX40s downstream targets that are directly involved in
cell replication and/or migration. To test whether DDX4
knockout in IM-9 cells changes the selected gene expression,
we undertook quantitative RT-PCR. The potential downstream
genes of interest included germline factors (ddx4 and piwil2)
and oncogene/cell cycle factors (14-3-3r, cyclinB1, e2f1, and
myc). Among those candidates, most transcripts were altered
minimally (Fig. 4a) whereas the cyclinB1, e2f1, and chi3 l1
transcripts were found consistently downregulated in the
DDX4-knockout cell lines, although still detectable.
To test whether DDX4 knockout indeed changes protein
expression of the above targets, we undertook immunoblots
against each molecule of interest (Fig. 4b). As a result, we
found that the positive cell cycle regulators CyclinB1 and
E2F1 were downregulated, whereas a negative cell cycle regu-
lator 14-3-3r was upregulated. As DDX4 is a translational
regulator, these results suggest that CyclinB and E2F1 mRNAs
could be targets of DDX4 and their protein production was
downregulated in the absence of DDX4. Indeed, CyclinB is
essential for M-phase entry and exit and has also been reported
as one of Vasa’s targets in embryonic cells.(15) Its knockdown,
therefore, may have blocked M-phase entry and indirectly
resulted in spindle defects. E2F1 is a transcription factor and
known to be highly active during the G1/S-phase transition,
yet some of its target genes also function in G2/M phase.
(28,29)
Therefore, the reduction of CyclinB and E2F1 proteins that are
critical for cell cycle progression might have caused cell pro-
liferation defects in DDX4-knockout cell lines. It is also
important to consider the phenotype observed here likely
includes both direct and indirect effects of DDX4 knockout,
because both DDX4 and some of its targets, including E2F1,
likely regulate a wide range of translation and transcription in
the cell. The further analysis of this process, including a broad
screening of DDX40s targets and cofactors by RNA immuno-
precipitation sequencing and proteomics is thus necessary to
parse out direct from indirect effects of DDX4 function. In
contrast, 14-3-3r is a cell cycle repressor. It is unclear what
increases its expression at this point in the DDX4-knockout.
DDX4 likely targets many mRNAs for translation and one
may thus speculate that DDX4 regulates a factor that sup-
presses 14-3-3r, and indirectly inhibits 14-3-3r protein
expression. This change could also cause cell cycle delay,
which is consistent with the phenotype seen in DDX4-knock-
out cell lines. Intriguingly, another germline factor PIWI was
Fig. 2. Construction of germline factor DDX4
knockout cell lines in IM-9 through clustered
regularly interspaced short palindromic repeats
(CRISPR)-Cas9 gene-targeting technology. (a) CRISPR
guide RNAs (gRNAs) were designed within the third
exon of the DDX4 gene to construct three
knockout cell lines (C1, C2, and C3). (b) (i) Genomic
PCR results for three CRISPR knockout cell lines
(C1–C3), control cells introduced with scrambled
gRNA sequence (SC), and original intact cells (ORI).
(ii) Genomic PCR results detecting lentiviral vector
sequence used for virus infection, showing effective
introduction of CRISPR constructs in C1–C3 and SC
cell lines. (c) DNA sequencing results of the third
exon and its flanking region of the DDX4 gene
depicted in (a). CRISPR knockout cell lines showed
deletions in many of the clones sequenced, whereas
controls of scrambled gRNAs showed no mutations.
(d) (i) Immunoblot results showing reduced DDX4
protein expression in knockout cell lines (C1–C3)
compared to control (SC). (e) Immunofluorescence
results showing reduced DDX4 protein expression in
knockout IM-9 cell lines (C1–C3) compared to
control (SC, arrows). Numbers underneath of each
image indicate the percentage of cells expressing
DDX4. The number of DDX4-positive cells per the
DAPI-positive cell number (a total cell population)
was calculated by Image J. The total numbers of
cells counted were: C1, 1222; C2, 1317; C3, 1471;
and SC, 1686. Scale bar = 5 lm. F, forward; R,
reverse.
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also upregulated in C1. As PIWI has been reported to target
various transcripts in the germ line for destruction,(30) the
overexpression of PIWI may have resulted in degradation of
mRNAs important for cellular activities, the mechanisms of
which need to be tested further in the future.
Vasa has been reported to have broad targets and function
as a general translational regulator in the embryo,(17) so we
tested whether DDX4 knockout inhibits general protein synthe-
sis (Fig. 4c). Each cell line was treated in methionine-depleted
media for 3 h with HPG (a tagged methionine analog) that is
incorporated into newly synthesized proteins and thus serves
as a good tool to measure the amount of nascent protein syn-
thesis. We found that the level of HPG incorporation was sig-
nificantly decreased in DDX4 knockout cell lines. These
results suggest that DDX4 might positively function in protein
synthesis as it does in embryonic or germ cells(17,31,32) and
help explain the phenotypic changes seen in the knockout
cells.
Discussion
DDX4 is essential for proliferation and migration activities in
somatic cancer cells. All animals tested so far appear to express
Vasa/DDX4 in their germ line at one point in their life. As its
knockdown often results in infertility, Vasa/DDX4 has been
considered and used as a germline marker for decades in the
field.(7–13) Its function in the germ line was also concluded to
be “germline-specific”, essential for functions in cell prolifera-
tion and migration of germ cells and translation of the mRNAs
in the germ cells. In this study, however, we reported that
DDX4 is widely expressed in several blood-derived cancer
cells and contributes to cell proliferation and migration. These
results directly suggest that DDX4 has functionalities outside
of the germ line, yet its expression may be limited to context-
specific periods of cellular development, to rapidly dividing
cells such as embryonic cells as reported previously, and in
human cancer cells as reported in this study.
DDX4/Vasa has also been reported to be transiently
expressed during regeneration,(19) the tissues of which also
undergo active cell proliferation and phenotypic changes. With
the results here, we might consider that DDX4 has various
downstream targets that are essential more generally for cell
proliferation and migration (Fig. 5). These results are also con-
sistent with Vasa’s activities in embryonic cells; Vasa has been
reported to regulate widespread translation essential for embry-
onic cell division and development.(17) Although what Vasa
does on the spindle has been unclear in any cell or organism
at this point, in embryonic cells, DDX4/Vasa appears to
Fig. 3. Knockout of germline factor DDX4 causes defects in cell proliferation and migration. (a) Cell number analysis shows reduced counts in
DDX4 knockout cell lines (C1, C2, and C3) compared to controls (scrambled [SC] and original intact cells [ORI]). This suggests that DDX4 might be
important for cell proliferation. (b) (i) Immunofluorescence using 5-Ethynyl-20-deoxyuridine (EdU) as indicator for DNA replication within knock-
out cell line C2 and control. Top panels shows consistent labeling of native DNA in C2 and control cells. Bottom panels show reduced DNA repli-
cation in C2 compared to the control. (ii) Graphical results of the DNA replication (EdU as indicator) in various cell lines in proportion with total
cell count, normalized to SC. (c) Graphical results of invasion assay in various cell lines, normalized to control (ORI). Results indicate that DDX4
might be important for cell migration.
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function as a general translational regulator rather than as a
regulator of specific targets. It is thus intriguing to speculate
that, in cancer cells and embryonic cells alike, DDX4/Vasa
may facilitate M-phase translation(33) on the spindle to assist
sufficient protein production necessary for rapid cell division.
This idea needs to be experimentally tested in the future by
manipulating Vasa function specifically on the spindle.
Through this mechanism, DDX4 could provide a molecular
environment for cancer cells to maximize proliferative activi-
ties and potentially contribute in neoplastic features of cancer
cells through upregulated protein expression. The thorough
screening of DDX40s downstream targets will be essential to
understand the details of DDX4 functions in cancer cell
regulation.
Another important question to be addressed in the future is
why DDX4/Vasa becomes essential only when it is expressed
in the cells. Not all cells, neither embryonic nor cancer cells,
appear to have DDX4/Vasa. Yet DDX4/Vasa expression, nor-
mally or abnormally induced, seems to change the cellular
dependency for translational activity to itself. Perhaps the
Fig. 4. Knockout of germline factor DDX4 caused little change in gene expression at the transcript level yet impacted protein expression. (a)
RT–quantitative PCR results for knockout cell lines (C1, C2, and C3) and two controls (scrambled [SC] and original intact cells [ORI]). DDX4 knock-
out showed little effect in oncogene expression at the transcript level. (b) Immunoblot results showing protein expression in DDX4 knockout cell
lines (C1–C3) and control (SC). In DDX4 knockout cells, positive cell cycle regulators CCNB1 (CyclinB1) and E2F1 were downregulated and nega-
tive cell cycle regulator 14-3-3r was upregulated. Germline factor PIWI was upregulated. (c) L-homopropargylglycine (HPG) labeling assay. C2
knockout cell line and control SC are shown as representative images of HPG assay (i). Knockout cell lines C1–C3 showed reduced HPG signal,
indicating nascent protein synthesis compared to the control SC, suggesting that DDX4 could have a role in positive protein regulation.
Fig. 5. Hypothetical models for the molecular
pathway of germline factor DDX4 (a) and for DDX4
function in cancer cells (b).
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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changes ensued by DDX4/Vasa expression might directly and
indirectly alter the global translational landscape in the cell.
We thus predict that other types of cancer cells that express
the DDX4 transcript, such as germ cell cancer, breast cancer,
and small-cell lung cancer (data not shown), may also depend
on its activity for survival. To be noted, DDX40s function is
heavily regulated by post-transcriptional regulation. Therefore,
it will be necessary to test its expression and localization at
the protein level in each of these cell lines. These further
exhaustive screenings as well as identification of the upstream
regulator(s) of DDX4 will be essential to understand how
DDX4 directly contributes to cellular activities of cancer cells.
Furthermore, as DDX4 is generally not expressed in benign
adult somatic cells,(14) it could serve as a potential target to
detect early steps of malignancy among heterogeneous tumors
and/or for a cancer therapy in the future. Our results suggest
that another germline factor, PIWI, also appears to be
expressed with DDX4 in these same cancer cells, and thus
may serve as important co-target for cancer therapy. The
detailed functional mechanisms of DDX4 with other germline
factors and its downstream targets needs to be tested further in
various cancer cell types and in patient tissues.
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